-
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares
climbed 41 percent to $5.23 after the company disclosed that Voclosporin met 48-week remission endpoints.
-
Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares
jumped 22.5 percent to $13.51 as the company reported the presentation of new data at the 2017 American Association for Cancer
Research Annual Meeting.
-
Infinity Pharmaceuticals Inc. (NASDAQ: INFI)
shares surged 21 percent to $3.63 as the company announced presentation on IPI-549 at the AACR Annual Meeting.
-
Navigator Holdings Ltd (NYSE: NVGS) jumped 20.9
percent to $13.30 on better-than-expected quarterly earnings.
-
GCP Applied Technologies Inc (NYSE: GCP) shares rose
17.8 percent to $31.05. GCP Applied Tech posted Q4 earnings of $0.29 per share on revenue of $332.9 million.
-
Ameresco Inc (NYSE: AMRC) gained 17.3 percent to
$6.10 after the company reported strong Q4 results.
-
Monster Beverage Corporation (NASDAQ: MNST)
jumped 15.4 percent to $48.49 after the company reported upbeat revenue for its fourth quarter.
-
Abercrombie & Fitch Co. (NYSE: ANF) rose 15 percent
to $13.45. Abercrombie & Fitch) reported weaker-than-expected earnings for its fourth quarter on Thursday. Its same-store sales
dropped 5 percent for the quarter, while comparable sales at Hollister rose 1 percent.
-
Intra-Cellular Therapies Inc (NASDAQ: ITCI)
gained 13.1 percent to $16.42 after the company reported a narrower-than-expected quarterly loss.
-
W&T Offshore, Inc. (NYSE: WTI) shares rose 13
percent to $2.96. W&T Offshore reported Q4 net income of $16.5 million.
-
Nektar Therapeutics (NASDAQ: NKTR) rose 12.9
percent to $14.69. Nektar Therapeutics reported a Q4 loss of $42.2 million.
-
CPI Card Group Inc (NASDAQ: PMTS) shares climbed
12.5 percent to $4.95 on upbeat Q4 results.
-
ACI Worldwide Inc (NASDAQ: ACIW) rose 11.5
percent to $21.98 on better-than-expected quarterly profit.
-
Vermillion, Inc. (NASDAQ: VRML) shares surged
11.1 percent to $2.61 after the company reported a contracted in-network agreement with Blue Cross Blue Shield of Michigan for
OVA1.
-
Superior Industries International Inc (NYSE: SUP)
gained 10.7 percent to $26.45 after the company posted upbeat Q4 results.
-
Glaukos Corp (NASDAQ: GKOS) shares climbed 10.5
percent to $50.60 after reporting strong Q4 results.
-
Acceleron Pharma Inc (NASDAQ: XLRN) rose 7.2
percent to $30.76. Acceleron Pharma posted a narrower-than-expected quarterly loss on Wednesday. Citigroup upgraded Acceleron
Pharma from Neutral to Buy.
-
Sarepta Therapeutics Inc (NASDAQ: SRPT) gained
6.1 percent to $32.23. Leerink Swann upgraded Sarepta Therapeutics from Market Perform to Outperform, while Nomura initiated
coverage on the stock with a Buy rating.
-
Ambac Financial Group, Inc. (NASDAQ: AMBC)
climbed 6 percent to $23.21. BTIG Research upgraded Ambac Financial from Neutral to Buy.
-
Ballard Power Systems Inc. (USA) (NASDAQ: BLDP)
shares rose 6 percent to $2.12 as the company posted stronger-than-expected results for its fourth quarter.
-
EXACT Sciences Corporation (NASDAQ: EXAS) rose
4.7 percent to $23.20. Exact Sciences and Mayo Clinic study showed a promise of new blood-based lung cancer test.
-
Methode Electronics Inc. (NYSE: MEI) rose 5.2
percent to $45.60 as the company posted upbeat quarterly earnings.
-
JD.Com Inc(ADR) (NASDAQ: JD) gained 4 percent to
$31.87. JD.com reported a Q4 loss of $0.18 per ADS on revenue of $11.558 billion. The company announced plans to sell 28.6
percent stake in JD Finance for RMB 14.3 billion in cash.
-
Burlington Stores Inc (NYSE: BURL) rose 3.5 percent
to $91.80 as the company reported upbeat results for its fourth quarter.
-
Broadcom Ltd (NASDAQ: AVGO) shares rose 3 percent
to $221.27 after the company reported stronger-than-expected results for its first quarter.
Latest Ratings for AUPH
Date |
Firm |
Action |
From |
To |
Nov 2016 |
Mackie Research |
Initiates Coverage On |
|
Speculative Buy |
Jun 2016 |
H.C. Wainwright |
Initiates Coverage on |
|
Buy |
Feb 2015 |
Leerink Swann |
Initiates Coverage on |
|
Outperform |
View More Analyst Ratings for
AUPH
View the Latest Analyst Ratings
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.